Foreign-trade zones allow pharma companies to hold imported inventory closer to U.S. demand while deferring duties and keeping market allocation open.
Commentary|Podcasts|November 27, 2024
Nov. 27 is Here: What Does That Mean for DSCSA?
Author(s)Nicholas Saraceno, Senior Editor
Nicholas Saraceno offers an overview of the legislation and how it impacts the pharma supply chain.
Advertisement
In this episode of The PC Podcast, Nicholas Saraceno, Pharma Commerce’s editor, explains:
- The history behind the Drug Supply Chain Security Act (DSCSA)
- The significance of Nov. 27
- The latest DSCSA exemptions and what that means for trading partners
- How this piece of legislation and AI are able to intertwine
The latest episode of The Pharmaceutical Commerce Podcast is available directly on
Advertisement
Related to this article
Octapharma USA's Kerem Tokel, a LogiPharma USA 2026 freight security panelist, discusses theft hotspots, the export of stolen pharmaceutical loads and how to tighten chain of custody.
In this week’s Pharma Pulse, GoodRx expands an employer offering built on manufacturer pricing for GLP-1 obesity drugs, a federal judge declines to block Lilly’s comparative Zepbound ads, and the PBM industry’s trade group turns the vertical integration debate toward drug wholesalers.
Why outdated paper prescribing information is creating unnecessary cost, complexity and friction across a modern pharmaceutical supply chain.
Episode 4 of Supply Chain Signal examines PhRMA’s legal challenge to CMS’ GLOBE model and whether manufacturers can lower costs, expand U.S. production and strengthen supply chain resilience all at once.
In this week's Pharma Pulse, Cencora agrees to acquire American Oncology Network, five major employers back electronic prior authorization for self-funded health plans and FDA finalizes its guidance on prescription drug apps and software.
CVS Health’s proposed separation of its retail pharmacy business from insurance and pharmacy benefit management raises a fundamental question: Will changing ownership improve pharmaceutical distribution, competition and patient access, or simply redistribute market power?
APIIC's Brian Doty says renovating shuttered US plants with advanced manufacturing is faster and cheaper than building new to reshore generics.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
CVS Health’s Breakup: A Turning Point for Pharma Supply Chains or a Redistribution of Market Power?
2
The End of the Traditional Launch: How JCA, HTA Evolution and Pricing Pressures Are Driving Continuous Evidence Generation
3
When Drug Pricing Collides With Politics
4
Idle US Capacity Could Anchor Generic Drug Reshoring, APIIC Says
5